cngrc peptide tnf alpha conjugate

Drug Overview

The CNGRC peptide-TNF alpha conjugate is a highly specialized, investigational cancer medication. It represents a new wave of medicine designed to outsmart cancer by attacking its life support system.

• Generic Name: CNGRC peptide-tumor necrosis factor alpha conjugate (often abbreviated as NGR-hTNF)
• US Brand Names: None yet. It is currently an investigational drug used in clinical trials and is sometimes referred to by its research names, such as Tengonermin, Zafiride, or Arenegyr.
• Drug Class: Antineoplastic Agent / Recombinant Fusion Protein / Targeted Therapy
• Route of Administration: Intravenous (IV) Infusion
• FDA Approval Status: Currently investigational. It is not yet FDA-approved for standard public use. However, it has been granted “Orphan Drug Status” by regulatory bodies for certain rare diseases, such as mesothelioma and liver cancer, to encourage its ongoing development.
  
  Discover the targeted cngrc peptide tnf alpha conjugate. Our hospital stays at the forefront of oncology to bring you the best treatment options.

What Is It and How Does It Work? (Mechanism of Action)

To understand this medication, it helps to know that tumors need a constant blood supply to grow. They build their own network of blood vessels to get food and oxygen.

The CNGRC peptide-TNF alpha conjugate is a “Smart Drug” and a “Targeted Therapy.” It is created in a lab by joining two different parts together:

1. TNF-alpha (Tumor Necrosis Factor-alpha): A powerful protein naturally found in the immune system that can damage tumor blood vessels and cause cancer cell death.
2. CNGRC Peptide: A tiny protein sequence that acts like a homing beacon or a GPS.

If doctors gave regular TNF-alpha directly to a patient, it would cause severe side effects all over the body. To solve this, scientists attached the CNGRC peptide to it.

Here is how it works at the molecular level:

• The Target: The blood vessels feeding a tumor look different from normal, healthy blood vessels. The tumor’s blood vessels have a high amount of a specific protein receptor on their surface called CD13 (or aminopeptidase N).
• The Lock and Key: The CNGRC peptide is specifically shaped to lock onto the CD13 receptors. After the drug is given through an IV, it floats through the bloodstream, ignoring healthy tissues, until it finds and binds directly to the CD13 receptors on the tumor’s blood vessels.
• The Attack: Once locked in place, the TNF-alpha part of the drug goes to work. It acts as a “capillary permeability modulator.” This means it breaks down the tight walls of the tumor’s blood vessels, making them leaky.
• The “Trojan Horse” Effect: By making the tumor’s blood vessels leaky, this Targeted Therapy creates open doors. This allows standard chemotherapy drugs and the body’s own immune cells (T-lymphocytes) to flood into the tumor much more easily, destroying the cancer from the inside out.

FDA-Approved Clinical Indications

Because this drug is currently an investigational agent, it does not have official FDA-approved indications for everyday clinical practice. However, it is being actively tested in clinical trials across the globe.

Oncological Uses (In Clinical Trials)

• Malignant Pleural Mesothelioma: Being tested as a treatment for this rare lung lining cancer caused by asbestos.
• Primary Central Nervous System Lymphomas (PCNSL): Being tested to help break the blood-brain barrier so other cancer drugs can reach tumors in the brain.
• Small Cell Lung Cancer (SCLC) and Non-Small Cell Lung Cancer (NSCLC): Used in patients whose cancer has returned after previous treatments.
• Ovarian Cancer: Tested in patients who are resistant to standard platinum-based chemotherapy.
• Advanced Solid Tumors: Investigated for liver, colorectal, kidney, and head and neck cancers.

Non-Oncological Uses

• There are currently no standard non-oncological uses being tested, as the drug is specifically designed to target the unique blood vessels formed by cancerous tumors.

Dosage and Administration Protocols

Because it is an investigational drug, the exact dosage depends on the specific clinical trial protocol. It is given in a hospital or clinic setting under close medical supervision.

Dose Adjustments for Organ Insufficiency:

Because the drug can interact with how the body handles other chemotherapy agents, doctors closely monitor liver and kidney function. In clinical trials, patients are generally required to have adequate baseline kidney and liver health (for example, bilirubin levels below 1.5 times the upper normal limit). If a patient has severe liver metastases, specialized dose adjustments or trial exclusions may apply.

Clinical Efficacy and Research Results

Recent clinical trial data (highlighted in ongoing research up to 2025) show that this drug works best as a team player, helping to overcome cancer that has become resistant to standard chemotherapy.

• Small Cell Lung Cancer (SCLC): In phase II trials combining NGR-hTNF with the chemotherapy drug doxorubicin for relapsed patients, the treatment showed a 25% partial response rate. The median progression-free survival (PFS) was roughly 3.2 months. Interestingly, the research showed that patients with a higher baseline count of lymphocytes (a type of immune cell) had a median overall survival time of 13.1 months, compared to 5.2 months for those with lower counts.
• Brain Lymphomas (PCNSL): In pilot studies treating brain lymphomas, giving this targeted drug alongside standard immunochemotherapy led to rapid and substantial tumor regression in 9 out of 12 patients. The drug successfully opened the blood-brain barrier just enough to let the life-saving chemotherapy reach the brain tumor.
• Disease Stabilization: In phase I trials for advanced solid tumors, while complete tumor shrinkage was rare when the drug was used entirely alone, a large percentage of patients (up to 66% in some study arms) experienced stable disease, meaning their tumors stopped growing for several months.

Safety Profile and Side Effects

A major benefit of this Targeted Therapy is that it uses very low doses to achieve its goal. Therefore, it usually avoids the severe, full-body side effects seen with older, untargeted TNF therapies.

Common Side Effects (>10%)

• Infusion-Related Reactions: Chills, mild fevers, or shivering (rigors) during or shortly after the IV drip.
• Blood Cell Changes: When combined with chemotherapy, it can increase the rate of neutropenia (low white blood cells) and anemia (low red blood cells).
• Fatigue: Mild to moderate tiredness following the infusion.

Serious Adverse Events

• Heart Function Changes (Rare): In some combination trials, temporary drops in the heart’s pumping ability (cardiac ejection fraction) have been noted.
• Severe Shortness of Breath (Dyspnea): This has generally only been seen when doctors tested very high doses (60 mcg/m²) during early safety trials.

Black Box Warning: There is no FDA Black Box Warning for this medication because it is still an investigational agent and not yet on the commercial market.

Management Strategies

• For Infusion Reactions: The medical team may give you medications like acetaminophen or antihistamines before your infusion to prevent chills and fevers.
• For Low Blood Counts: Doctors will perform regular blood tests. If white blood cells drop too low, they may delay the next treatment or provide medications to boost your immune system.

Connection to Stem Cell and Regenerative Medicine

While the CNGRC peptide-TNF alpha conjugate is not a stem cell therapy itself, it has a strong connection to the world of Immunotherapy and advanced cellular treatments. A major challenge in treating solid tumors with advanced cellular medicine (like CAR-T cell therapy) is that tumors build a thick, high-pressure physical wall around themselves, preventing healing immune cells from getting inside. Because this targeted drug selectively breaks down the tumor’s blood vessel barriers, it is being heavily researched as a “door opener.” By altering the tumor microenvironment, it paves the way for the body’s own T-lymphocytes—or artificially engineered immune cells—to successfully infiltrate the tumor bed and destroy the cancer.

Patient Management and Practical Recommendations

To ensure safety and the best possible outcome during clinical trials, patients must follow specific medical guidelines.

Pre-treatment Tests to be Performed

• Blood Panels: Comprehensive tests to check liver function, kidney function, and complete blood counts (CBC).
• Cardiac Testing: An echocardiogram (ECHO) or MUGA scan to ensure your heart is pumping strongly, especially if the drug is being combined with certain chemotherapies like doxorubicin.
• Pregnancy Test: A required negative test for women of childbearing age, as the therapy could be harmful to a developing fetus.

Precautions During Treatment

• You will be closely monitored by nurses during the 60-minute infusion to watch for any sudden chills or fever.
• Because this drug can lower your white blood cell count when combined with chemo, you must be highly cautious about catching infections.

“Do’s and Don’ts” List

• DO drink plenty of fluids and stay hydrated before and after your treatment days.
• DO report any fever, chills, or shortness of breath to your healthcare team immediately, even if it happens days after you go home.
• DON’T receive any “live” vaccines without getting strict permission from your oncologist first.
• DON’T ignore minor signs of infection, such as a sore throat or a small cut that becomes red, as your immune system may be temporarily weaker.

Legal Disclaimer

The information provided in this guide is for educational and informational purposes only and does not constitute medical advice. CNGRC peptide-TNF alpha conjugate (NGR-hTNF) is an investigational agent and is not currently approved by the US Food and Drug Administration (FDA) or the European Medicines Agency (EMA) for general clinical use. It is available only through participation in approved clinical trials or expanded access programs. Always consult with a qualified healthcare professional or your treating oncologist regarding diagnosis, treatment options, potential risks, and your eligibility for clinical trials.